HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Marc Miravitlles Selected Research

moxifloxacin (Avelox)

7/2012Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.
1/2010Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
1/2010Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life.
12/2009Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study.
7/2008Moxifloxacin: a respiratory fluoroquinolone.
1/2007Determining factors in the prescription of moxifloxacin in exacerbations of chronic bronchitis in the primary-care setting.
1/2007[Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD

Marc Miravitlles Research Topics

Disease

24Chronic Obstructive Pulmonary Disease (COPD)
12/2012 - 09/2002
6Chronic Bronchitis
07/2012 - 08/2005
2Respiratory Tract Infections (Respiratory Tract Infection)
02/2009 - 07/2008
1Dementia (Dementias)
08/2012
1Heart Failure
08/2012
1Emphysema
03/2012
1Pneumonia (Pneumonitis)
07/2008
1Airway Obstruction (Choking)
12/2006
1Dyspnea (Shortness of Breath)
04/2006

Drug/Important Bio-Agent (IBA)

7moxifloxacin (Avelox)FDA Link
07/2012 - 01/2007
4Anti-Bacterial Agents (Antibiotics)IBA
01/2008 - 03/2004
3Carbon MonoxideIBA
12/2012 - 08/2004
3Amoxicillin (Wymox)FDA LinkGeneric
10/2012 - 01/2009
3Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric
10/2012 - 01/2009
3GoldIBA
10/2010 - 04/2006
3tiotropium (Spiriva)FDA Link
10/2009 - 06/2007
2Bronchodilator Agents (Bronchodilators)IBA
03/2012 - 12/2006
2Biological Markers (Surrogate Marker)IBA
05/2011 - 01/2010
1OxygenIBA
08/2012
1Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)FDA Link
07/2012
1Fibrinogen (Factor I)FDA Link
01/2010
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2010
1Interleukin-6 (Interleukin 6)IBA
01/2010
1Interleukin-8 (Interleukin 8)IBA
01/2010
1formoterol (Oxis)FDA Link
10/2009
1Budesonide (Pulmicort)FDA LinkGeneric
10/2009
1MacrolidesIBA
02/2009
1QuinolonesIBA
02/2009
1Immunoferon (AM3)IBA
05/2008
1Ipratropium (Ipratropium Bromide)FDA LinkGeneric
06/2007
1salmeterol (Serevent)FDA Link
06/2007
1Adrenal Cortex Hormones (Corticosteroids)IBA
04/2006
1DNA (Deoxyribonucleic Acid)IBA
09/2002
1Epoxide HydrolasesIBA
09/2002

Therapy/Procedure

1Artificial Respiration (Mechanical Ventilation)
01/2012
1Drug Therapy (Chemotherapy)
01/2009
1Activities of Daily Living (ADL)
02/2007